The use of finerenone into a triple treatment regimen comprising RAAS, SGLT-2, and MR inhibitors demonstrates potential in markedly postponing CKD development and mitigating residual interstitial inflammation (Zhu et al., 2023). This evidence concerns the gene NR3C2 and chronic kidney disease.